NCT02192944View on ClinicalTrials.gov

Comparison of the ECG Effects Related to Pharmacokinetic Profile of Chloroquine and Piperaquine

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Healthy
Interventions
DRUG

Chloroquine

Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.

DRUG

Dihydroartemisinin-piperaquine

Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.

Trial Locations (1)

10400

Faculty of Tropical Medicine, Mahidol University, Bangkok

All Listed Sponsors
lead

University of Oxford

OTHER

NCT02192944 - Comparison of the ECG Effects Related to Pharmacokinetic Profile of Chloroquine and Piperaquine | Biotech Hunter | Biotech Hunter